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 Patient: Female, 11
 Final Diagnosis: Bullous pemphigoid in systemic lupus erythematosus
 Symptoms: Bullous lupus • photosensitive rash • synovitis
 Medication: —
 Clinical Procedure: Pharmacological treatment
 Specialty: Rheumatology
 Objective: Unusual clinical course
 Background: Bullous pemphigoid is an autoimmune blistering disease, with relapses, isolated or associated with other au-
toimmune diseases such as systemic lupus erythematosus (SLE). Joint manifestations rapidly respond to small 
or moderate doses of corticosteroids, whereas skin manifestations usually respond to antimalarial drugs.
 Case Report: We describe the clinical case of an 11-year-old girl with SLE. She showed bullous skin lesions with arthralgia, 
mild proteinuria, resolved after steroid treatment. At the tapering of her prednisone dose, the patient had new 
skin lesions requiring an increased dose of prednisone. She started dapsone at the dosage of 1 mg/kg/day, 
maintaining low dose prednisone; this treatment was successfully followed by the dramatic disappearance of 
skin lesions and limb pain.
 Conclusions: Bullous skin lesions can represent the first clinical presentation of pediatric SLE and could influence the treat-
ment and the outcome of these patients.
  This case showed an atypical course as both skin manifestations and arthritis promptly and persistently re-
solved with dapsone without the use of high-dose glucocorticoids.
  Only a few cases of patients with SLE associated with bullous pemphigoid have been reported in the literature, 
and very few in the pediatric population.
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Background
Bullous pemphigoid (BP) is an autoimmune blistering disease. 
Isolated BP exhibits a relatively benign prognosis with relaps-
es, but may be associated with other autoimmune diseases in 
the context of complex clinical syndromes [1,2].
Skin and joint involvement are frequent manifestations of sys-
temic lupus erythematosus (SLE). There are three forms of cu-
taneous SLE: chronic cutaneous (discoid) lupus, subacute cu-
taneous lupus, and acute cutaneous lupus. Joint involvement 
is typically not erosive. Anti-Ro is closely associated with a 
photosensitive rash and with subacute lupus. Joint manifes-
tations rapidly respond to small or moderate doses of corti-
costeroids [3], whereas skin manifestations usually respond 
to antimalarial drugs [2,4,5].
Only few cases of patients with SLE associated with BP have 
been reported in the literature [6,7], and very few in the pedi-
atric population [8–15].
Case Report
We describe the case of an 11-year-old female with SLE. She 
had a history of periodic fevers, recurrent joint swelling and 
tenderness (knees and ankles), back pain, abdominal pain, and 
a butterfly rash. She developed mild proteinuria, which was suc-
cessfully treated with steroids. Since the age of 10 years, she 
had developed a vesiculobullous eruption with clinical and his-
tological features of BP, with typical skin features (Figure 1A). 
Biopsy of a bulla revealed subepidermal blister, and perivascu-
lar neutrophils and eosinophil infiltration. She showed a persis-
tent high titer of anti-dsDNA antibodies (345 IU/mL by ELISA, 
nv <100), and anti-nuclear antibodies (1: 160 by IFI). Her ENA 
(anti-Ro, LA, RNP), anti-desmoglein 1, 3 antibodies, anti-BP 
180, anti-BP 230, anti-skin-AMB, and anti-skin-ASI antibodies 
were negative. The genetic study of auto-inflammatory syn-
dromes (FMF, TRAPS; MVK, NLRP3, NLRP12) was negative. For 
the skin lesions relapses, she received corticosteroids (pred-
nisone 1 mg/kg/day) resulting in the remission of the clinical 
manifestations (Figure 1B) and the normalization of serum 
amyloid A (SAA), erythrocyte sedimentation rate (ESR), and 
C-reactive protein (CRP). At the tapering of prednisone dose, 
the patient had new skin lesions requiring an increased dose. 
She showed striae rubrae, hypertrichosis, and growth velocity 
reduction. Due to the frequent relapses, she started oral ad-
ministration of dapsone at the dosage of 1 mg/kg/day, which 
resulted in dramatic disappearance of the lesions and allowed 
gradual dose tapering of prednisone down to 2.5 mg/day. She 
subsequently showed an increase of growth velocity, a puber-
tal onset, and menarche, which occurred seven months after 
the start of dapsone. During the first 18 months of follow-up 
she manifested four relapses of the skin lesions associated 
with knee and back pain. However dermatological lesions af-
ter dapsone treatment were mild, and promptly resolved with 
short courses of low-dose oral prednisone.
Discussion
We described an unusual presentation of pediatric SLE with bul-
lous skin lesions. The association between SLE and pemphigoid 
is uncommon in the pediatric population, with only 10 cases re-
ported in the literature [8–15]. Moreover, while cutaneous lupus 
responds to hydroxychloroquine, a satisfactory outcome with 
dapsone treatment has only sporadically been reported [4,5]. 
In the described case, dapsone treatment showed efficacy on 
skin lesions and the treatment was followed also by the com-
plete remission of the other manifestations of the disease, with-
out the employment of other immunosuppressive drugs [16].
Conclusions
In our patient, this therapy allowed a good control of clinical 
outcome with a low dose of steroids in a phase of her life char-
acterized by growth spurt and pubertal development.
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Figure 1.  (A) Severe skin lesions before dapsone treatment. (B) Skin lesions after start of steroids treatment (prednisone 1 mg/kg/day).
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For patients at the adolescent age, in fact, steroid doses should 
be low and only given for brief periods. This care prevents de-
lay in bone maturation and impaired pubertal development.
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